Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab for polymyalgia rheumatica
2017-002989-42Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing Sarilumab plus shorter prednisone taper with Placebo plus longer prednisone taper (2 arms). Primary endpoint: Proportion of patients achieving sustained remission. Started Oct 2018; status: terminated.
02
Drugs
sarilumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2017-002989-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002989-42.